The strength of the genetic association between specific MHC class II alleles and an individual's susceptibility to particular chronic inflammatory diseases renders these alleles the main known risk ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity.

Major histocompatibility complex (MHC) class II–restricted antigen presentation is essential for the function of dendritic cells (DCs). We show here that plasmacytoid DCs (pDCs) differ from all other ...

The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in ...

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.

Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...

Which came first, MHC class I or MHC class II? For decades, it has been debated which of these two similar classes came first in evolution. Now, Keiichiro Hashimoto and his group at Fujita Health ...

Lung immunity is essential to combat all pulmonary diseases, including COVID-19, pneumonia, lung cancer, asthma, and COPD. Lung immunity differs from the systemic immunity which is the normal focus of ...

Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types. This is an ASCO Meeting Abstract from the ...

A new study published on the preprint server bioRxiv* analyzed the mechanisms by which two SARS-CoV-2 accessory proteins, ORF3a and ORF7a, can downregulate the expression of major histocompatibility ...